Thomas W Flaig, Philippe E Spiess, Michael Abern, Yi An, Rick Bangs, Jovan Begovic, Jason Brown, Mark K Buyyounouski, Kevin Chan, Paul Chang, Arnold I Chin, Khurshid A Guru, Harry W Herr, Jean Hoffman-Censits, Hristos Kaimakliotis, Shilajit Kundu, Subodh M Lele, Amy Luckenbaugh, Jonathan Maldonado, Lin Mei, Jeffrey S Montgomery, Mamta Parikh, Anthony Patterson, Charles Peyton, Elizabeth R Plimack, Mark A Preston, Kyle Richards, Steven Seyedin, Arlene O Siefker-Radtke, Tyler Stewart, Debasish Sundi, Umang Swami, Matthew Tollefson, Jonathan L Wright, Carly J Cassara, Bailee Sliker
{"title":"Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.","authors":"Thomas W Flaig, Philippe E Spiess, Michael Abern, Yi An, Rick Bangs, Jovan Begovic, Jason Brown, Mark K Buyyounouski, Kevin Chan, Paul Chang, Arnold I Chin, Khurshid A Guru, Harry W Herr, Jean Hoffman-Censits, Hristos Kaimakliotis, Shilajit Kundu, Subodh M Lele, Amy Luckenbaugh, Jonathan Maldonado, Lin Mei, Jeffrey S Montgomery, Mamta Parikh, Anthony Patterson, Charles Peyton, Elizabeth R Plimack, Mark A Preston, Kyle Richards, Steven Seyedin, Arlene O Siefker-Radtke, Tyler Stewart, Debasish Sundi, Umang Swami, Matthew Tollefson, Jonathan L Wright, Carly J Cassara, Bailee Sliker","doi":"10.6004/jnccn.2026.0022","DOIUrl":null,"url":null,"abstract":"<p><p>The NCCN Guidelines for Bladder Cancer provide strategies for the diagnosis, treatment, and follow-up of patients with bladder cancer, which is the sixth most common cancer in the United States. Bladder cancer can be divided into 3 categories along a clinical spectrum: (1) non-muscle-invasive bladder cancer; (2) muscle-invasive bladder cancer; and (3) metastatic bladder cancer, with most patients falling into the category of non-muscle-invasive disease. Thus, the selected content featured in this issue specifically covers the clinical presentation and workup of and subsequent management recommendations for non-muscle-invasive bladder cancer.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"186-203"},"PeriodicalIF":16.4000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network : JNCCN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jnccn.2026.0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The NCCN Guidelines for Bladder Cancer provide strategies for the diagnosis, treatment, and follow-up of patients with bladder cancer, which is the sixth most common cancer in the United States. Bladder cancer can be divided into 3 categories along a clinical spectrum: (1) non-muscle-invasive bladder cancer; (2) muscle-invasive bladder cancer; and (3) metastatic bladder cancer, with most patients falling into the category of non-muscle-invasive disease. Thus, the selected content featured in this issue specifically covers the clinical presentation and workup of and subsequent management recommendations for non-muscle-invasive bladder cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
